Biotechnology
Primrose Bio Launches Prima Rnapols Extend Cap AU, A Next-Gen RNA Polymerase For Self-Amplifying Mrna
Share
Maximize capping efficiency and minimize double-stranded RNA ("dsRNA") in the manufacturing of self-amplifying mRNA
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols™ ExTend Cap AU, an RNA polymerase engineered to significantly improve manufacturing of self-amplifying mRNA vaccines and therapeutics.
ExTend Cap AU enables high-yield, fully capped self-amplifying mRNA with less capping reagent, template DNA and RNA polymerase. Built specifically for AU cap analogs, dsRNA reduction combined with lower reagent needs delivers higher quality, more cost-effective mRNA.
Key Features & Benefits
- High AU capping efficiency: Achieves high capping efficiency with less cap, lowering reagent requirements
- Ultra-low dsRNA: Minimizes unwanted IVT byproducts, reducing downstream purification needs
- Higher yield of saRNA: Maximizes yield while maintaining integrity and fidelity compared to T7 polymerases
- Cost-efficient manufacturing: Uses less template, enzyme, and cap analog for significant cost savings
"Although saRNA products have already achieved regulatory approval in Japan and Europe, developers need improved tools to produce long template mRNA with higher fidelity and purity, while reducing reagent and downstream purification costs," said Drew Burch, CEO of Primrose. "Primrose's enzyme evolution toolkit enables this new solution, so our customers can develop better saRNA products with more efficient manufacturing to address infectious disease, oncology, and other disease states."
Prima RNApols ExTend Cap AU is available for research use applications. GMP-grade Prima RNApols manufactured and released under ISO 13485:2016 certified quality systems are available for clinical and commercial mRNA manufacturing. For more information, please visit www.prima.primrosebio.com.
About Primrose Bio, Inc.
Primrose Bio is focused on developing and commercializing its validated technologies that address industry gaps in production systems and deliver scalable, efficient manufacturing solutions. Primrose major offerings include Prima RNApols™: improved enzymes for mRNA manufacturing; Pfenex Expression Technology®: a proprietary production system used in six approved products with up to 20x higher yields and unparalleled success in making complex proteins; and PeliCRM197®: a commercially validated CRM197 carrier protein used for conjugate vaccines. Several of the world's leading pharmaceutical companies use Primrose's technologies, including Merck, Jazz Pharmaceuticals, Alvogen, Serum Institute of India, Arcellx, Arcturus and others. For more information, please visit www.primrosebio.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/primrose-bio-launches-prima-rnapols-extend-cap-au-a-next-gen-rna-polymerase-for-self-amplifying-mrna-302609657.html
SOURCE Primrose Bio
Frequently Asked Questions
What is Prima RNApols ExTend Cap AU?
It is an engineered RNA polymerase designed to improve the manufacturing of self-amplifying mRNA vaccines and therapeutics.
What are the key benefits of using ExTend Cap AU?
High AU capping efficiency, ultra-low dsRNA, higher yield of saRNA, and cost-efficient manufacturing.
Is ExTend Cap AU available for commercial use?
Yes, GMP-grade Prima RNApols are available for clinical and commercial mRNA manufacturing.
First published on Mon, Nov 10, 2025
Enjoyed what you read? Great news – there’s a lot more to explore!
Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!
Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.
Head to the TechDogs homepage to Know Your World of technology today!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
The Home Depot And Google Cloud Launch Agentic AI Tools To Help Customers And Associates Bring Projects From 'How-To' To 'Done'
UOG (United One Group) Wins Three Prestigious Industry Awards At CES 2026
Broadridge Invests In Deepsee, Further Harnessing Agentic AI To Transform Post-Trade Operations
NAVEE Unveils High-Performance Mobility Innovations And Expands Into Outdoor Scenarios At CES 2026
PROMISE Technology To Showcase AI-Ready Storage Infrastructure For Smart City And IVA Surveillance At Intersec Dubai 2026
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion